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ABSTRACT:
Background:  Antibiotic use is recommended within the 2015 guidelines during chronic
obstructive pulmonary disease (COPD). However, controversy remains as to whether they truly
lead to improved outcomes.
Objective: The primary objective is a reduction in 30-day readmission rate for those receiving
antimicrobial therapy for a COPD exacerbation. Secondary objectives include 90-day
readmission rate, time to next COPD exacerbation and length of hospital stay.
Methods: 322 subjects were evaluated in this Institutional Review Board approved,
retrospective study. Patients ≥18 years-old admitted to the hospital in non-intensive care
nursing units for a primary or secondary diagnosis of a COPD exacerbation were included.
Exclusion criteria included transfer from an outside hospital, evidence of acute decompensated
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heart failure, immunocompromised state, diagnosis of pneumonia and/or influenza,
documented past medical history of other lung disease(s), hospitalization within the past 90
days, code status of comfort measures only or expectation of death within 48 hours, active
pregnancy or lactation, current status as a prisoner, and patients with miscoded records.
Results: 30-day readmission rates were no different for those who did/did not receive
antibiotic therapy (12.7% vs. 10.3%, p=1.00). Additionally, there was no difference in 90-day
readmission rate (11.3% vs 13.8%, p=0.74) and time to next exacerbation (104.7 days vs
138.1 days, p=0.41). Length of stay was no different (3.6 days vs 3.0 day) but a trend toward
significance was noted (p=0.06)
Conclusion: The exact role of antibiotics on the reduction of readmission rates and length of
stay in the management of recurrent COPD exacerbations remains uncertain.
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INTRODUCTION
The use of antibiotics during an acute moderate to severe chronic obstructive pulmonary
disease (COPD) exacerbation is common practice. Currently, antibiotic use is recommended
within the Global Initiative for COPD (GOLD) guidelines for specific patients in an attempt to
achieve improved outcomes and symptom management.  The three cardinal symptoms of a
COPD exacerbation include the presence of increased dyspnea, sputum purulence, and/or
increased sputum volume.  These three cardinal symptoms are more specifically referred to
as the Anthonisen type I criteria, with type II criteria including a change in any two of the
cardinal symptoms.  Antibiotic therapy is recommended if all three or two of the three
symptoms are present, provided sputum purulence or the need for mechanical ventilation is
one of them.  A recent trial investigating the use of the Anthonisen criteria to guide therapy
found that increased sputum purulence was a predictor of clinical failure in patients not treated
with antibiotics.  The study also demonstrated that C-reactive protein (CRP) measurements
significantly increased the predictive accuracy of clinical failure.  Given that most
exacerbations are due to bacterial infections that result in airway and systemic inflammation; a
reduction in CRP can be an indication that antimicrobial therapy is effectively eradicating the
infectious organism(s).
Approximately 50% of all COPD exacerbations are secondary to bacterial infections.
Whereas the airways of a majority of patients with stable COPD can be colonized with
bacteria, exacerbations are thought to be triggered by acquisition of new bacterial strains.
The common pathogens present during COPD exacerbations were Streptococcus
pneumoniae, Hemophilus influenzae, Moraxella catarrhalis and  Pseudomonas aeruginosa.
H. influenzae is present in up to 30% of all COPD exacerbations and compared to colonizing
strains, strains of H. influenzae present during exacerbations are capable of increased
adherence to epithelial cells and increased production of inflammatory markers.  For this
reason the presence of purulent sputum during an exacerbation is highly correlated with a
bacterial infection. Recent studies have shown that sputum purulence alone may be a
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sufficient indicator to initiate antibiotics.  Obtaining sputum cultures prior to initiating
antimicrobial therapy is not always possible and inaccuracies in sampling techniques and/or
assessment of quality of the sputum specimens may lead to the overuse of broad-spectrum
therapy.  However, current guidelines do recommend that, if a COPD exacerbation has not
improved after treatment with antibiotics, a sputum culture be obtained to assist in assessing
bacterial eradication.
Furthermore, five-year all-cause mortality rates as high as 50% have been found following a
hospital admission for a COPD exacerbation.  In addition, the frequency of exacerbations
increases as COPD progresses, with patients experiencing an average of 1-2 exacerbations
per year.  A systematic review published by Ram and colleagues evaluating antimicrobial
therapy in COPD exacerbations demonstrated reductions in short-term mortality by 77%,
treatment failure by 53% and sputum purulence by 44%.  Along with disease progression,
health status of hospitalized patients declined more quickly following a hospital admission,
resulting in an elevated risk of mortality during the subsequent 90 days following each severe
episode.
Once the decision has been made to initiate antimicrobial therapy, many treatment options
exist. Several recent studies having shown that early initiation of antibiotic therapy is beneficial
in improving patient symptoms but specific antibiotic choice does not affect overall clinical
outcomes.  However, given previous studies of varying quality and patient populations,
controversy still remains over whether or not antibiotics truly lead to improved clinical outcomes
in patients experiencing a COPD exacerbation and if beneficial,  which antibiotic regimen
results in the best clinical outcomes.
METHODS
This is an Institutional Review Board approved retrospective study, evaluating all patients ≥ 18
years-old admitted to non-intensive care nursing units for a primary or secondary diagnosis of
COPD at a 335-bed, tertiary academic medical center. Exclusion criteria included transfer from
an outside hospital, evidence of acute decompensated heart failure, immunocompromised
state (i.e. solid organ transplant recipients, presence of HIV or AIDS, the use of any biologic
agent within the past 60 days, use of high-dose corticosteroids for ≥2 weeks (20 mg/day
prednisone or equivalent within the past 3 months)), concomitant diagnosis of pneumonia or
influenza, documented past medical history of other lung disease(s) (i.e. tuberculosis, cystic
fibrosis, primary ciliary dyskinesia, bronchiectasis), active malignancy, previous hospitalization
within the past 90 days for any reason, code status of comfort measures only or expectation of
death within 48 hours of admission, active pregnancy or lactation, current status as a prisoner,
and patients with miscoded records. ICD-9 codes were utilized for patient identification and
data collection. Data was collected for patients admitted between 1/01/2013 and 12/31/2014.
Patients were stratified into two groups according to whether or not they received antibiotics
during their hospital admission.   In addition to the presence of the above-mentioned
information, the following information was collected: age, gender, place of residence, smoking
status, number of previous admissions for COPD exacerbation within the past 12 months of
admission, use of oral and/or intravenous (IV) antibiotics and/or corticosteroids within the past
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30 days of admission, as well as all baseline comorbid conditions, presence/absence of
cardinal COPD symptoms, and most recent documented forced expiratory volume (FEV).
The primary outcome of the study was to evaluate the impact of antibiotic therapy on reducing
30-day readmission rates for a recurrent COPD exacerbation. Secondary outcomes included
readmission rates within 90 days for a recurrent COPD exacerbation, length of hospital stay,
in-hospital mortality, and time to next exacerbation.
Statistical analysis: Data collected included discrete and continuous variables. The Chi-square
or Fisher exact tests were used to compare categorical variables. The Student’s t-test and
Wilcoxon rank-sum test were used to compare normally distributed and non-normally
distributed variables, respectively. A p-value of <0.05 was considered a statistically significant
difference. Statistical analysis was generated using Statistical Analysis Software (SAS),
Version 9.2 for Windows. Copyright  2002-2008. SAS Institute Inc., Cary, NC, USA.
COPD and Antibiotics - Figure 1
Figure 1: Patient Enrollment
RESULTS
A total of 322 patients were screened for study inclusion, and 100 patients met all inclusion
and exclusion criteria (Figure 1). The majority of excluded patients had concomitant diagnosis
of pneumonia (25%) or were hospitalized within the preceding 90 days (22%). Baseline
characteristics are shown in Table 1. No significant differences were found between the two
groups with regards to their baseline characteristics; however, there was a non-significant
increase in the percentage of patients in the no antibiotic group having been treated with either
antibiotics (37.9%) or corticosteroids (51.7%) in the 30 days prior to admission. The mean age
of the patient population was 74 years (range 24-87) with a slightly larger percentage of
patients being female (58.6%) in the no-antibiotic group vs. those receiving antibiotics (51.2%).
The majority of patients were former smokers (66.2% in the antibiotic group, 72.4% in the no
antibiotic group) and the median Charlson Comorbidity Index was 2 (range 0-9). The median
CRP was 61.5 mg/L in the antibiotic group and 37.5 mg/L in the no antibiotic group.  In those
patients who did receive antibiotics upon admission, 68% (N=48) did not present with the
Anthonisen criteria and had a median CRP value was 85.6 mg/L.
Table 1. Baseline Characteristics
Antibiotics
 N=71
No
antibiotics
N=29
p-
value
Age (years), mean [range] 75 [24-94] 73 [48-90] 0.70
Gender (male), % 47.9 41.4 0.66
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Smoker, %:
•       Current
•       Former
•       Never
 
28.2
66.2
5.6
 
24.1
72.4
3.4
 
0.80
Forced expiratory volume in 1 second (FEV1) prior to admit,
median
49 46.5 0.72
Charlson comorbidity index, median 2 2 0.44
Antibiotics 30 days before admission, % 18.3 37.9 0.07
Steroids 30 days before admission, % 31 51.7 0.07
Hospitalization for COPD exacerbation over past 12 months, % 12.7 17.2 0.52
# COPD exacerbations over past 12 months, mean:
•       1-3
•       >3
 
45.1
4.2
 
48.3
10.3
 
0.43
Anthonisen criteria, N (%)
•       Yes
•       No
 
23 (32)
48 (68)
 
7 (24)
22 (76)
 
0.48
Of the 100 patients included in the study, 71% (N=71) were treated with antibiotics, while 29%
(N=29) were not.  Specifically, 67.6% (N=48) received azithromycin monotherapy, 12.7%
(N=9) received doxycycline monotherapy and 19.7% (N=14) received levofloxacin
monotherapy, In the antibiotic group, 12.7% of patients were readmitted for a recurrent COPD
exacerbation within 30 days compared to 10.3% in the no antibiotics group (p=1.0) (Figure 2).
No significant differences were found between those patients who received antibiotics and
those that did not with regards to the secondary outcomes (Table 2). Specifically, the 90 day
readmission rate for a COPD exacerbation was 11.3 % (received antibiotics) versus 13.8%
(did not receive antibiotics), p=0.74 and mean time to next COPD exacerbation 104.6 days
versus 138.1 days, (p=0.41). There was a non-statistically significant trend toward reduction in
the mean length of hospital stay for those who did not receive antibiotics (3.0 days) versus
those that did (3.6 days), p=0.06. In addition to the use of antibiotics, the majority of patients in
each group were prescribed steroids during admission (97% in the antibiotic group and 96.6%
in the no antibiotic group). Lastly, there were no instances of in-hospital mortality in either of
the groups.
COPD and Antibiotics - Figure 2
Figure 2: Primary Outcome
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Table 2: Secondary Outcomes
Antibiotics
N=71
No antibiotics
N=29
p-value
90-day readmission rate for COPD exacerbation, % 11.3 13.8 0.74
Length of hospital stay (days), mean 3.6 3.0 0.06
Time to next COPD exacerbation (days), mean 104.7 138.1 0.41
CONCLUSION/DISCUSSION
Overall, no statistically significant difference in the 30-day readmission rate for a recurrent
COPD exacerbation was found between those subjects that received antibiotics and those that
did not in this study. In addition, no significant difference was found between the two groups
with regards to the secondary outcomes including 90-day readmission rate and time to next
exacerbation. However, a trend toward a significantly shorter mean length of hospital stay was
seen in the patients who did not receive antibiotics compared to those who did receive
antibiotics. Additionally, it can be seen that approximately two-thirds of those patients who
received antibiotics did not have the presence of one, or more, of the cardinal symptoms of
COPD. Thus, in this cohort of patients the guidelines do not support the use of antibiotics,
exposing these patients to, potentially, unnecessary adverse effects, increased risk of drug
resistance and overall antibiotic exposure.
In a review by Vollenweider and colleagues, the rate of treatment failure was assessed in
patients experiencing a COPD exacerbation treated with, and without, antibiotics.  The
authors evaluated three groups of patients, those admitted as non-intensive care (ICU)
inpatients, intensive care unit patients, and outpatients, from sixteen trials comparing
antibiotics to placebo with a primary endpoint of treatment failure between seven and thirty
days. From this student it was shown that antibiotic use reduced the risk of treatment failure for
hospitalized patients, including those admitted to an ICU, but not for those patients managed
in an outpatient setting. In addition, there was no significant effect on in-patient mortality and
length of hospital stay.  Severity of COPD and stratifying patients according to risk factors for
prescribing antibiotics has been recommended; however, this is often not feasible especially in
retrospective studies. Additionally, Vollenweider and colleagues did not collect data on risk
factors and severity of COPD, consistent with the present study.   Additionally, a smaller
study by Lode and colleagues found no significant differences in exacerbation-free interval for
one year when comparing the use of levofloxacin versus clarithromycin in patients
experiencing a COPD exacerbation.  As has been demonstrated in the literature, significant
variety exists between the antimicrobial regimen(s) used to manage COPD exacerbations,
making it difficult to demonstrate superiority of any one regimen.
At our institution, a patient-specific COPD order set is available to facilitate management of
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acute exacerbations for the non-critically ill patient. This order set guides providers to select
either oral or IV azithromycin at a dose of 500 mg x one with four additional days of 250 mg or
doxycycline 100 mg twice daily for 7 days. Additionally, the recommended drug, dose and
duration of corticosteroid is prednisone 40 mg daily for 5 days. It should be noted that the order
set provides guidance on these, and other clinical areas including, but not limited to, the use of
bronchodilators but allows providers to customize the drug, dose and frequency within each
choice as the clinical case dictates. For each patient, providers indicate if the use of antibiotics
is warranted. If there is no evidence of a bacterial infection, then the provider would indicate
that antibiotics are not needed. However, if there is evidence of a bacterial infection, then the
provider would indicate on the order set that the use of antibiotics is deemed appropriate, and
they have the option of choosing either macrolide therapy, which is preferred, or alternatively
doxycycline may be used. The COPD order set was used in 42% of patients in the antibiotic
group and only 24% of patients in the no antibiotic group, demonstrating a need for further
education on its appropriate use relative to initiation of antibiotics.
Additionally, other studies assessing time to next exacerbation often compared two different
antibiotic groups, rather than a treatment and control group, making it difficult to compare the
results of the present study to those in which all patients received antimicrobial therapy. Impact
of long-term antimicrobial therapy may also affect outcomes due to resistance patterns and
overall bacterial colonization. Lastly, our study only evaluated the rate of COPD re-
exacerbation for a period of time up to 90 days, whereas several studies followed patients for
up to 12 months, or longer. Thus, a direct comparison cannot be made between these studies.
Limitations of this study include its retrospective design and the concern that patients may
have sought care at outside facilities, and therefore documentation of a readmission would not
be available as part of this review, exists. A variety of subjective assessments were present
throughout this study due to patient-reported symptoms, provider documentation of these
symptoms, and then investigator bias in reviewing and interpreting these documented
symptoms.  Additionally, the lack of  other clinical markers to guide the use of antimicrobial
therapy in this cohort, such as C-reactive protein, may have impacted the number of patients
who inappropriately received antibiotic therapy. Lastly,  the limited use of CRP to guide clinical
decision making during the studied time period. A total of eight subjects had a recorded CRP
during this time, limiting our ability to fully comment on the use of this biomarker to guide
antibiotic therapy. Since 2014 a higher percentage of patients have a recorded CRP hospital-
wide, as this was added as part of the admission laboratory process.  Overall, this study did
not find a difference in the 30 day readmission rate for recurrent non-critical COPD
exacerbations in patients treated with antibiotics compared to those treated without antibiotics.
In addition, there was a trend toward a slightly longer mean length of stay in the antibiotic
group compared to the no antibiotic group. Given the small sample it is difficult to quantify this
result, combined with the fact that there was no difference in Charlson Comorbidity Index or
corticosteroid use between these patients. Providers may be reluctant to discharge a patient
until they have received several days of antibiotics, thus increasing the length of stay in this
cohort, however this is speculation. Overall, the benefit of antibiotics on the reduction of
readmission rates for a recurrent COPD exacerbation and length of stay remains uncertain.
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Until more definitive evidence is available, clinicians should use appropriate clinical judgment
in addition to the most up-to-date clinical literature when evaluating the need for antibiotic use
in individual patients presenting with a COPD exacerbation.
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